Zoetis (ZTS) Stock Price, Fundamentals & Analysis

What ZTS does

Zoetis (ZTS) is a stock in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Headquartered in Parsippany, United States, the company engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for the animal health industry. It markets products to veterinarians, livestock producers, and pet owners across the United States and internationally. Zoetis is part of the S&P 500.

Key numbers explained

• $71.61 is the current price per share, representing the cost to buy one unit of the company.
• The trailing P/E ratio of 11.7 shows how much investors pay per dollar of the company's last 12 months of earnings; a lower number can suggest a cheaper valuation relative to recent earnings.
• The forward P/E ratio of 11 uses expected future earnings, offering a look at how the market prices the company's growth outlook.
• 2.91% is the dividend yield, which measures the annual cash payout relative to the share price, indicating the income return for shareholders.
• -48.6% is the price change over the last 52 weeks, showing the total return from one year ago to today.
• 27.7% is the profit margin, meaning the company keeps 27.7% of its revenue as profit after all expenses.
• 0.73 is the beta, a measure of volatility; a beta below 1 suggests the stock tends to move less than the overall market.
• The debt-to-equity ratio of 294% indicates the company uses significant debt relative to shareholder equity, which is common in large, established firms.

Recent news

Recent headlines highlight that Zoetis (ZTS) stock dropped despite market gains, with its fair value falling after mixed analyst cuts and softer growth views. The company stands by its guidance as it faces pet-care weakness and competition pressure on sales. Additionally, notable investor Michael Burry has made a new bet on ZTS.

What to watch

Investors typically monitor the animal health industry's competitive landscape, including how Zoetis responds to pressure from rivals like Labcorp (LH) and Regeneron Pharmaceuticals (REGN). The company's upcoming earnings report on Nov 3, 2026 will be a key event. Broader factors such as veterinary spending trends, new product launches, and macroeconomic conditions that affect healthcare and consumer discretionary sectors also influence this kind of stock.